An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Details
Age
Adult
Locations
University of Colorado Hospital
Principal Investigator
Brad Haverkos
Study ID
Protocol Number: 22-0565
More information available at ClinicalTrials.gov: NCT05011058
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers